Top-Rated StocksTop-RatedNASDAQ:EXAS Exact Sciences (EXAS) Stock Price, News & Analysis $51.55 +4.39 (+9.31%) Closing price 04:00 PM EasternExtended Trading$51.68 +0.13 (+0.24%) As of 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Exact Sciences Stock (NASDAQ:EXAS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Exact Sciences alerts:Sign Up Key Stats Today's Range$49.94▼$54.7150-Day Range$40.31▼$50.1852-Week Range$39.97▼$72.83Volume6.91 million shsAverage Volume2.63 million shsMarket Capitalization$9.58 billionP/E RatioN/ADividend YieldN/APrice Target$69.90Consensus RatingModerate Buy Company OverviewExact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.Read More… Exact Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks90th Percentile Overall ScoreEXAS MarketRank™: Exact Sciences scored higher than 90% of companies evaluated by MarketBeat, and ranked 90th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingExact Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.95, and is based on 19 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageExact Sciences has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Exact Sciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Exact Sciences are expected to grow in the coming year, from ($0.58) to $0.50 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Exact Sciences is -9.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Exact Sciences is -9.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioExact Sciences has a P/B Ratio of 3.99. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.88% of the float of Exact Sciences has been sold short.Short Interest Ratio / Days to CoverExact Sciences has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in Exact Sciences has recently decreased by 3.94%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldExact Sciences does not currently pay a dividend.Dividend GrowthExact Sciences does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.83 Percentage of Shares Shorted5.88% of the float of Exact Sciences has been sold short.Short Interest Ratio / Days to CoverExact Sciences has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in Exact Sciences has recently decreased by 3.94%, indicating that investor sentiment is improving. News and Social Media2.8 / 5News Sentiment1.06 News SentimentExact Sciences has a news sentiment score of 1.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.83 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 30 news articles for Exact Sciences this week, compared to 11 articles on an average week.Search InterestOnly 4 people have searched for EXAS on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Exact Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Exact Sciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.36% of the stock of Exact Sciences is held by insiders.Percentage Held by Institutions88.82% of the stock of Exact Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Exact Sciences' insider trading history. Receive EXAS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exact Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address EXAS Stock News HeadlinesExact Sciences Q1 Earnings: Decent Quarter, But Growth Story Not CompellingMay 2 at 1:09 PM | seekingalpha.comCancer Diagnostic Firm Exact Sciences' CEO Says Strong Q1 Paves Way For 'Transformative' 2025, Lifts Annual GuidanceMay 2 at 9:18 AM | benzinga.comTrump Makes Major Crypto AnnouncementTrump's Pro-Crypto Agenda Finally Sparks Market Recovery With Bitcoin surging past $90,000 and altcoins heating up, I'm seeing all the signs of a major market shift For a limited time, I'm revealing the name and complete analysis behind my top Trump-era crypto pick. May 2, 2025 | Crypto 101 Media (Ad)Exact sciences raises 2025 revenue guidance to $3.12B driven by Cologuard Plus launchMay 2 at 8:33 AM | msn.comExact Sciences to Participate in May Investor ConferenceMay 2 at 6:00 AM | businesswire.comExact Sciences Corporation (EXAS) Q1 2025 Earnings Call TranscriptMay 1 at 9:02 PM | seekingalpha.comExact Sciences Corporation 2025 Q1 - Results - Earnings Call PresentationMay 1 at 8:47 PM | seekingalpha.comExact Sciences climbs on full year guidance raise, revenue beatMay 1 at 7:56 PM | msn.comSee More Headlines EXAS Stock Analysis - Frequently Asked Questions How have EXAS shares performed this year? Exact Sciences' stock was trading at $56.19 at the start of the year. Since then, EXAS stock has decreased by 8.3% and is now trading at $51.55. View the best growth stocks for 2025 here. How were Exact Sciences' earnings last quarter? Exact Sciences Co. (NASDAQ:EXAS) released its quarterly earnings data on Thursday, May, 1st. The medical research company reported ($0.21) EPS for the quarter, topping analysts' consensus estimates of ($0.37) by $0.16. Exact Sciences's revenue for the quarter was up 10.9% on a year-over-year basis. Read the conference call transcript. Does Exact Sciences have any subsidiaries? The following companies are subsidiaries of Exact Sciences: Ashion Analytics, Thrive Earlier Detection Corporation, Base Genomics Limited, Paradigm Diagnostics Inc., Viomics Inc., Biomatrica Inc., Armune BioScience, and more. Who are Exact Sciences' major shareholders? Exact Sciences' top institutional investors include Principal Financial Group Inc. (0.42%), Peregrine Capital Management LLC (0.38%), Sumitomo Mitsui Trust Group Inc. (0.31%) and EULAV Asset Management (0.18%). Insiders that own company stock include Kevin T Conroy, Sarah Condella, Katherine S Zanotti, James Edward Doyle, Everett Cunningham, D Scott Coward, Daniel J Levangie, Jacob A Orville, Brian Baranick, Jeffrey Thomas Elliott and James Herriott. View institutional ownership trends. How do I buy shares of Exact Sciences? Shares of EXAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Exact Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Exact Sciences investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Adobe (ADBE) and Arista Networks (ANET). Company Calendar Last Earnings5/01/2025Today5/02/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryBiotechnology Current SymbolNASDAQ:EXAS CIK1124140 Webwww.exactsciences.com Phone(608) 284-5700Fax608-284-5701Employees6,400Year Founded1995Price Target and Rating Average Stock Price Target$69.80 High Stock Price Target$90.00 Low Stock Price Target$52.00 Potential Upside/Downside+35.7%Consensus RatingModerate Buy Rating Score (0-4)2.95 Research Coverage22 Analysts Profitability EPS (Most Recent Fiscal Year)($5.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-204,150,000.00 Net Margins-37.29% Pretax Margin-37.56% Return on Equity-5.29% Return on Assets-2.45% Debt Debt-to-Equity Ratio0.97 Current Ratio2.15 Quick Ratio1.93 Sales & Book Value Annual Sales$2.76 billion Price / Sales3.46 Cash Flow$5.85 per share Price / Cash Flow8.79 Book Value$12.93 per share Price / Book3.98Miscellaneous Outstanding Shares185,755,000Free Float182,559,000Market Cap$9.55 billion OptionableOptionable Beta1.14 Social Links Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:EXAS) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exact Sciences Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exact Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.